- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01095250
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis (INSURE)
October 5, 2015 updated by: Novartis Pharmaceuticals
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4G5
- Novartis Investigative Site
-
North York, Ontario, Canada, M3N 2V6
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Novartis Investigative Site
-
-
-
-
-
Cairo, Egypt
- Novartis Investigative Site
-
-
-
-
-
Nantes, France, 44093
- Novartis Investigative Site
-
-
-
-
-
Freiburg, Germany, 79106
- Novartis Investigative Site
-
Göttingen, Germany, D-37075
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, 1083
- Novartis Investigative Site
-
-
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380004
- Novartis Investigative Site
-
-
-
-
-
Afula, Israel, 18101
- Novartis Investigative Site
-
Petach Tikva, Israel, 49100
- Novartis Investigative Site
-
Ramat Gan, Israel, 52621
- Novartis Investigative Site
-
Tel-Aviv, Israel, 64239
- Novartis Investigative Site
-
-
-
-
-
Kyoto, Japan, 602-8566
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka-city, Fukuoka, Japan, 812-8582
- Novartis Investigative Site
-
-
Fukushima
-
Fukushima-city, Fukushima, Japan, 960-1295
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo-city, Hokkaido, Japan, 060-8648
- Novartis Investigative Site
-
-
Osaka
-
Osaka-city, Osaka, Japan, 545-8586
- Novartis Investigative Site
-
Suita-city, Osaka, Japan, 565-0871
- Novartis Investigative Site
-
-
Tochigi
-
Shimotsuka-gun, Tochigi, Japan, 321-0293
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- Novartis Investigative Site
-
Mitaka-city, Tokyo, Japan, 181-8611
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08036
- Novartis Investigative Site
-
-
-
-
-
Bern, Switzerland, 3010
- Novartis Investigative Site
-
Bern, Switzerland, 3012
- Novartis Investigative Site
-
Luzern, Switzerland, 6000
- Novartis Investigative Site
-
St. Gallen, Switzerland, 9007
- Novartis Investigative Site
-
-
CHE
-
Lausanne, CHE, Switzerland, 1004
- Novartis Investigative Site
-
-
-
-
-
York, United Kingdom, YO31 8HE
- Novartis Investigative Site
-
-
-
-
California
-
Beverly Hills, California, United States, 90211
- Novartis Investigative Site
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02142
- Novartis Investigative Site
-
-
New York
-
Slingerlands, New York, United States, 12159
- Novartis Investigative Site
-
-
Texas
-
Arlington, Texas, United States, 76012
- Novartis Investigative Site
-
Houston, Texas, United States, 77025
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects ≥18 years of age. Where relevant, parents will also sign the informed consent according to local laws and regulations
- Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye
- Evidence of active intermediate, posterior or panuveitis (grade ≥ 2+ vitreous haze with or without the presence of anterior chamber cells) at screening and baseline in at least one eye
- Requirement for any of the following immunosuppressive therapies for the treatment or prevention of uveitis:
- Prednisone or equivalent ≥10 mg daily at any time within the past 3 months.
- ≥1 periocular injection or ≥1 intravitreal corticosteroid injection (e.g. triamcinolone) in the study eye within the past 6 months (the last injection must not have been given 6 weeks prior to screening).
- Treatment with either cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate at any time within the past 3 months (Patients treated with chlorambucil or cyclophosphamide within the past 5 years are ineligible for the study).
- Patients not meeting the above specified criteria for immunosuppressive therapies are eligible for enrollment if they are intolerant to systemic immunosuppressive therapy as determined by the study investigator.
- Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
Exclusion Criteria:
Ocular concomitant conditions/disease
- Patients receiving or that may require prednisone (or equivalent) ≥1.5 mg/kg/day for the treatment of their active uveitis
- Patients with a primary diagnosis of Behcet's disease, anterior uveitis or any intermediate uveitis, posterior uveitis or panuveitis in which the manifestation(s) of the active intraocular inflammatory disease may spontaneously resolve or that are not characterized by the presence of either anterior chamber cells or vitritis (vitreous cell and haze) such as the white dot retino-choroidopathies (i.e. Punctate inner choroidopathy (PIC), acute zonal occult outer retinopathy (AZOOR)
- Patients with infectious uveitis or uveitis of an underlying diagnosis that is uncertain and would reasonably include a disease for which immunosuppression would be contraindicated (e.g. ocular lymphoma)
Ocular treatments
- Treatment with intravitreal anti-VEGF agents administered to the study eye within 3 months prior to screening
- Treatment with fluocinolone acetonide implant in the study eye within the last 3 years, or dexamethasone intravitreal implant and any other investigational corticosteroid implants in the study eye within the last 6 months.
- Intraocular surgery or laser photocoagulation in the study eye within the last 6 weeks prior to screening except for a diagnostic vitreous or aqueous tap with a small-gauge needle
- Ocular disease that would interfere with ocular evaluations (e.g. corneal scarring, cataract, vitreous hemorrhage) or that in the opinion of the investigator would complicate the evaluation of the safety or efficacy of the study treatment (e.g. uncontrolled glaucoma, toxoplasma scar, macular scarring)
- Current use of or likely need for systemic medications known to be toxic to the lens, retina, or optic nerve (e.g., deferoxamine, chloroquine, ethambutol, etc.)
Systemic conditions or treatments
- Any previous treatment with AIN457
- Any systemic biologic therapy (e.g. interferon, infliximab, daclizumab, etanercept, or adalimumab) given intravenously or subcutaneously within 3 months prior to screening. No biologic therapy other than the investigational study treatment will be allowed during the course of the clinical trial
- Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil) within the past 5 years prior to screening
- Treatment with any live or live-attenuated vaccine (including vaccine for varicella-zoster or measles) within 2 months prior to screening. No treatment with live or live-attenuated vaccines will be allowed during the course of the clinical trial
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AIN457 300mg s.c every 2 weeks
AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
|
|
Experimental: AIN457 300mg s.c. every 4 weeks
AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
|
|
Experimental: AIN457 150mg s.c every 4 weeks
AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
|
|
Placebo Comparator: Placebo s.c every 2 weeks
Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Vitreous Haze Grade in the Study Eye From Baseline to 28 Weeks or at Time of Rescue, if Earlier.
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Responders With no Recurrence of Active Intermediate, Posterior, or Panuveitis in the Study Eye at 28 Weeks
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Mean Change in Best Corrected Visual Acuity From Baseline to 28 Weeks
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Change From Baseline in Quality of Life/Patient Reported Outcome Assessments
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Mean Change in Vitreous Haze Grade and Anterior Chamber Cell Grade From Baseline to 28 Weeks
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Change in Immunosuppressive Medication Score From Baseline to Week 28
Time Frame: baseline to 28 weeks
|
No patients of Study CAIN457C2303 achieved the milestone of the primary endpoint in non-infectious uveitis patients with Behçet's disease.
Study CAIN457C2302 (active uveitis study) was terminated to avoid continuing patients on a study with a low probability of success.Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
|
baseline to 28 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
March 25, 2010
First Submitted That Met QC Criteria
March 26, 2010
First Posted (Estimate)
March 30, 2010
Study Record Updates
Last Update Posted (Estimate)
November 3, 2015
Last Update Submitted That Met QC Criteria
October 5, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAIN457C2302
- 2009-014834-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitis
-
Priovant Therapeutics, Inc.Active, not recruitingNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan UveitisUnited States
-
University of NebraskaUnknownPosterior Uveitis | Intermediate Uveitis | Pan-uveitisUnited States
-
Stanford UniversitySanten Inc.WithdrawnPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
CHU de Quebec-Universite LavalCompletedIntermediate Uveitis | Anterior UveitisCanada
-
EyePoint Pharmaceuticals, Inc.CompletedPanuveitis | Posterior Uveitis | Intermediate UveitisIndia
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Novartis PharmaceuticalsCompletedNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious PanuveitisUnited States, United Kingdom
-
Duke UniversityCompletedPosterior Uveitis | Intermediate UveitisUnited States
-
AllerganCompletedPosterior Uveitis | Intermediate UveitisFrance, United Kingdom, United States, Spain, Poland, India, South Africa, Korea, Republic of, Canada, Czech Republic, Australia, Germany, Israel, Switzerland, Portugal, Austria, Brazil, Greece
-
The New York Eye & Ear InfirmaryUnknownPanuveitis | Uveitis | Posterior Uveitis | Anterior UveitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States